NFE2L2 and central nervous system cancer: As for the expression in glioma, the results are shown in Fig. 1, KEAP1 and NFE2L2 showed a near 2~3 fold increase in both GBM and LGG, and the NOX4 showed a nearly 20-fold increase in GBM.